CALGARY, Feb. 19, 2013 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics")
(TSX:ONC; NASDAQ:ONCY) announced today its intention, subject to market and
other conditions, to commence an underwritten public offering of common
shares. The number of common shares to be distributed and the price of each
common share will be determined in the context of the market with final terms
to be determined at the time of pricing.
Piper Jaffray & Co. and Wedbush PacGrow Life Sciences will act as joint
book-running managers for the offering in the U.S. and Paradigm Capital Inc.
will act as co-manager in the U.S. and book-running manager in Canada. The
Company expects to grant the underwriters participating in the offering a
30-day option to purchase up to an additional 15 percent of the number of
common shares sold pursuant to the offering to cover over-allotments, if any.
The offering is subject to market conditions, and there can be no assurance as
to whether or when the offering may be completed, or as to the actual size or
terms of the offering.
Oncolytics intends to use the net proceeds from the offering to fund its
clinical trial program, manufacturing program and for general corporate and
working capital purposes.
The common shares are being offered in each of the Canadian provinces of
British Columbia, Alberta, Manitoba and Ontario by way of a prospectus
supplement to the Company's base shelf short form prospectus and in the United
States pursuant to a prospectus supplement to the Company's effective shelf
registration statement on Form F-10 (333-182260) previously filed with the
United States Securities and Exchange Commission. Copies of the prospectus
supplement and accompanying base prospectus relating to the offering may be
obtained from the Securities and Exchange Commission website at
http://www.sec.gov, from the System for Electronic Document Analysis and
Retrieval (SEDAR) website at http://www.sedar.com or from the underwriters at:
Piper Jaffray & Co.
800 Nicollet Mall, J12S03, Minneapolis, MN 55402
Telephone: (800) 747-3924
Wedbush Securities Inc.
One Bush Street, 17th floor, San Francisco, CA 94104, Attn: SF Prospectus
Before you invest, you should read the prospectus supplement and accompanying
prospectus, the registration statement, and the other documents that the
Company has filed with the Securities and Exchange Commission for more
complete information about the Company and this offering.
This press release does not and shall not constitute an offer to sell or the
solicitation of an offer to buy any of the securities, nor shall there be any
sale of the securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration of qualification
under the securities laws of any state or jurisdiction.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development
of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical
program includes a variety of human trials including a Phase III trial in head
and neck cancers using REOLYSIN(®), its proprietary formulation of the human
This press release contains forward-looking statements within the meaning of
the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act
of 1934, as amended, and forward-looking information within the meaning of
Canadian securities laws. Statements, other than statements of historical
facts, included in this press release that address activities, events or
developments that Oncolytics expects or anticipates will or may occur in the
future, including such things as the proposed offering of common shares and
the intended use of proceeds and other such matters are forward-looking
statements and forward-looking information and involve known and unknown risks
and uncertainties, which could cause the Company's actual results to differ
materially from those in the forward-looking statements and forward-looking
information. Such risks and uncertainties include, among others, risks related
to the market conditions of the offering and risks related to the Company's
business which may result in the intended use of proceeds changing. Investors
should consult the Company's quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and
uncertainties relating to the forward-looking statement and forward-looking
information. Investors are cautioned against placing undue reliance on
forward-looking statements and forward-looking information. The Company does
not undertake to update these forward-looking statements and forward-looking
information, except as required by applicable laws.
Oncolytics Biotech Kirk Look 210, 1167 Kensington Cr NW Calgary, Alberta T2N
1X7 Tel: 403.670.7377 Fax: 403.283.0858 email@example.com
The Equicom Group Nick Hurst 300 5th Ave. SW, 10th Floor Calgary, Alberta
T2P 3C4 Tel: 403.218.2835 Fax: 403.218.2830 firstname.lastname@example.org
Dian Griesel, Inc. Susan Forman 396 West Broadway, 2nd Floor New York, NY
10012 Tel: 212.825.3210 Fax: 212.825.3229 email@example.com
SOURCE: Oncolytics Biotech Inc.
To view this news release in HTML formatting, please use the following URL:
CO: Oncolytics Biotech Inc.
NI: BTC NEWSTK
-0- Feb/19/2013 21:01 GMT
Press spacebar to pause and continue. Press esc to stop.